Clinical trialPhase 2Completed
Abraxane Therapy in Patients With Pancreatic Cancer Who Failed First-Line Gemcitabine Therapy
Phase II Trial of Abraxane® in the Treatment of Patients With Pancreatic Cancer Who Have Failed First-Line Treatment With Gemcitabine-Based Therapy
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- June 2008
- Expected end
- December 2012
- Enrollment
- 20 participants
- Sites
- 2
- Primary outcomes
- Overall Survival Rate at 6 Months
- Sponsor
- Other
- Results posted
- 2013-11-15
- Last update
- 11 May 2017
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 1
- Registry-listed results paperA phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. DOI 10.1097/coc.0b013e3182436e8c↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.